Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: This study aimed to report bimekizumab (BKZ) efficacy and safety in Japanese patients with generalised pustular psoriasis (GPP) and erythrodermic psoriasis (EP).
Methods: Patients aged ≥ 18 years with plaque psoriasis, GPP, or EP received BKZ for 144 weeks; only results for GPP and EP reported here. All patients received BKZ 320 mg every 4 weeks (Q4W) at week 0, with dose adjustments for Q4W or Q8W at weeks 16 and 48, depending on Investigator's Global Assessment (IGA) 0/1 response. Efficacy outcomes assessed to week 144: IGA 0/1, Dermatology Life Quality Index (DLQI) 0/1, Clinical Global Impressions-Improvement (CGI-I), ≥ 75/90/100% improvement from baseline Psoriasis Area and Severity Index (PASI 75/90/100), ≥ 75/90/100% improvement from baseline modified Nail Psoriasis Severity Index (mNAPSI 75/90/100), and patient-reported outcomes; GPP-specific outcomes: Japanese Dermatological Association (JDA) severity index and Global Improvement Score (GIS). Treatment emergent adverse events (TEAEs) evaluated through weeks 0-144 and safety follow-up.
Results: At week 144, most patients with GPP (8/10) and EP (10/11) completed the study. At week 16, all patients reported efficacy outcomes improving with BKZ, generally persisting through week 144. At week 144 (missing visit: 1 GPP), 6/7 patients with GPP and 8/10 with EP achieved IGA 0/1; 5/7 and 9/10 patients achieved DLQI 0/1; 7/7 and 9/10 patients achieved CGI-I response ("improved"/"remission"); and 6/7 and 9/10 patients achieved PASI 90, respectively; 2/5 patients with GPP and 4/9 with EP achieved week 144 mNAPSI 100. Among patients with GPP, JDA severity index generally decreased and improvements in GIS were sustained to week 144. Serious TEAEs were observed in 2/10 patients with GPP and 5/11 with EP; BKZ was well tolerated with low incidence of TEAEs leading to study discontinuation (2 GPP, 1 EP).
Conclusions: Long-term BKZ treatment over 3 years improved signs and symptoms of GPP and EP; these were sustained through week 144. No new safety signals were identified.
Trial Registration: ClinicalTrials.gov identifier, NCT03598790.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13555-025-01509-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies.
Front Immunol
September 2025
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Introduction: Cutaneous manifestations in adult-onset immunodeficiency (AOID) resulting from anti-interferon-gamma autoantibody (AIGA) are prevalent and can be classified into infective and reactive disorders. To date, no clinical studies have specifically examined pustular reaction in patients with AOID. This study aimed to provide an original characterization of the clinical manifestations associated with pustular reaction in AOID and to compare these features with those observed in a clinically similar entity, generalized pustular psoriasis (GPP).
View Article and Find Full Text PDFClinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study.
Ann Dermatol Venereol
September 2025
Department of Dermatology, René Dubos Hospital, Pontoise, France.
Background: Generalized pustular psoriasis (GPP) is a rare, severe, chronic neutrophilic skin disease involving the interleukin-36 (IL-36) pathway.
Objective: The main objective of the SCRIPTOR international non-interventional study was to describe sociodemographic and clinical characteristics of GPP. This paper focuses on data collected from participating French centers.
Risk-based analytical quality control of chemotherapy preparations: A simulation and FMECA approach.
J Oncol Pharm Pract
September 2025
Laboratory of Excellence for Innovations in Biotechnology, Pharmaceutical Bioengineering, and Artificial Intelligence, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakesh, Morocco.
IntroductionEnsuring the analytical quality control of chemotherapy preparations is essential to patient safety and treatment efficacy. However, the risk of preparation errors remains a critical concern in hospital pharmacy. Failure Mode, Effects, and Criticality Analysis (FMECA) is a structured risk assessment tool that can help identify, evaluate, and mitigate potential failures.
View Article and Find Full Text PDFEconomic burden and cost drivers of generalized pustular psoriasis: a systematic review.
Health Econ Rev
September 2025
Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Unlabelled: Generalized pustular psoriasis (GPP), as a rare type of life-threatening psoriasis with currently no effective treatment, imposes a huge economic burden on the healthcare systems. This systematic review aimed to summarize studies on the economic burden of GPP and the corresponding key cost drivers. A systematic search was conducted on PubMed, Web of Science, and Scopus for eligible studies published between 1st January 2000 and 31st December 2024.
View Article and Find Full Text PDFReal-world treatment patterns in patients with generalized pustular psoriasis (GPP).
J Am Acad Dermatol
August 2025
Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Background: Generalized pustular psoriasis (GPP) is a chronic and life-threatening inflammatory skin disease, distinct from plaque psoriasis (PsO). There is a lack of GPP treatment guidelines.
Objective: To characterize treatment patterns among patients with GPP in the US during two 365-day periods (post-diagnosis and pre-diagnosis) between 2015 and 2020.